Oculis, a clinical-stage biotechnology company focused on the development of non-invasive topical treatment for back-of-the-eye diseases, announced it has successfully closed a Series B financing round of CHF 20 million. In conjunction with the financing, Oculis is re-locating its corporate headquarters to Lausanne.
Find an actor

MEDICA 201812.11.2018

MEDICA 2018 will be back in Düsseldorf from 12 to 15 November.

"Hidden estrogen receptors in the breast epithelium"

"EPFL scientists have uncovered that next to estrogen receptor-positive and -negative cells, there are cells with very...
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn